Asia
The company indicates there was “a trend toward less bleeding with edoxaban, though, results did not show statistical superiority.”
A fully integrated biopharmaceutical company - Uni-Bio Science Group Limited are pleased to announce that its interim results for the period ended 30 June 2019
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Researchers from A*STAR’s Institute of Bioengineering and Nanotechnology have developed a customisable hydrogel that cultivates patient-derived tumour organoids which can better mimic the original.
Alcohol-Free Wipe for Eliminating Viruses and Bacteria on Personal Belongings
TLC announced that the management team is scheduled to present at the two upcoming investor conferences
CrystalGenomics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CG-745, a clinical stage histone deacetylase (HDAC) inhibitor being developed for several hematologic malignancies and solid tumors, for the treatment of patients with pancreatic cancer.
Eisai Co., Ltd. announced that it provides tanks to supply clean water for the neglected tropical diseases (NTDs) measuresto the endemic regions in Kenya in collaboration with Merck.
Great Bay Bio is pleased to announce that following the successful establishment of the 3D Advisory Board in the middle of this month, the Science Sub-Committee welcomes another new key member, Dr. Mark McHale, to the team.
ASLAN Pharmaceuticals today announced that a late-breaking abstract detailing results from a phase 2 study of varlitinib in patients with advanced or metastatic biliary tract cancer in China has been accepted for oral presentation at the upcoming 2019 Chinese Society of Clinical Oncology (CSCO) in Xiamen, China on 19 September 2019.
PRESS RELEASES